Glycoconjugate Journal Special Issue On: the Glycobiology of Parkinson's Disease

Overview

Journal Glycoconj J

Publisher Springer

Specialties Biochemistry
Endocrinology

Date 2021 Nov 10

PMID 34757539

Citations 1

Authors

Inka Brockhausen

John Schutzbach

Jiabei Wang

Beth Fishwick

Jennifer Brockhausen

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that affects over 10 million aging people worldwide. This condition is characterized by the degeneration of dopaminergic neurons in the pars compacta region of the substantia nigra (SNpc) and by aggregation of proteins, commonly α-synuclein (SNCA). The formation of Lewy bodies that encapsulate aggregated proteins in lipid vesicles is a hallmark of PD. Glycosylation of proteins and neuroinflammation are involved in the pathogenesis. SNCA has many posttranslational modifications and interacts with components of membranes that affect aggregation. The large membrane lipid dolichol accumulates in the brain upon age and has a significant effect on membrane structure. The replacement of dopamine and dopaminergic neurons are at the forefront of therapeutic development. This review examines the role of membrane lipids, glycolipids, glycoproteins and dopamine in the aggregation of SNCA and development of PD. We discuss the SNCA-dopamine-neuromelanin-dolichol axis and the role of membranes in neuronal stem cells that could be a regenerative therapy for PD patients.

Citing Articles

Protein profiling of extracellular vesicles from iPSC-derived astrocytes of patients with ALS/PDC in Kii peninsula.

Kobayashi H, Ueda K, Morimoto S, Ishikawa M, Leventoux N, Sasaki R Neurol Sci. 2023; 44(12):4511-4516.

PMID: 37615876 DOI: 10.1007/s10072-023-07000-7.

References

Gai W, Yuan H, Li X, Power J, Blumbergs P, Jensen P . In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol. 2000; 166(2):324-33. DOI: 10.1006/exnr.2000.7527. View

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S . Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015; 14(8):855-866. PMC: 5217462. DOI: 10.1016/S1474-4422(15)00006-X. View

Videira P, Castro-Caldas M . Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson's Disease. Front Neurosci. 2018; 12:381. PMC: 5999786. DOI: 10.3389/fnins.2018.00381. View

Li J, Uversky V, Fink A . Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology. 2002; 23(4-5):553-67. DOI: 10.1016/s0161-813x(02)00066-9. View

Poklar Ulrih N, Barry C, Fink A . Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties. Biochim Biophys Acta. 2008; 1782(10):581-5. DOI: 10.1016/j.bbadis.2008.07.004. View

Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C . Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat. 2010; 31(7):763-80. PMC: 3056147. DOI: 10.1002/humu.21277. View

Alcalay R, Levy O, Waters C, Fahn S, Ford B, Kuo S . Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015; 138(Pt 9):2648-58. PMC: 4564023. DOI: 10.1093/brain/awv179. View

Do J, McKinney C, Sharma P, Sidransky E . Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019; 14(1):36. PMC: 6716912. DOI: 10.1186/s13024-019-0336-2. View

Yap T, Gruschus J, Velayati A, Westbroek W, Goldin E, Moaven N . Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem. 2011; 286(32):28080-8. PMC: 3151053. DOI: 10.1074/jbc.M111.237859. View

10.

Ledesma M, Martin M, Dotti C . Lipid changes in the aged brain: effect on synaptic function and neuronal survival. Prog Lipid Res. 2011; 51(1):23-35. DOI: 10.1016/j.plipres.2011.11.004. View

11.

Andersson M, Appelkvist E, Kristensson K, Dallner G . Distribution of dolichol and dolichyl phosphate in human brain. J Neurochem. 1987; 49(3):685-91. DOI: 10.1111/j.1471-4159.1987.tb00948.x. View

12.

Ward W, Guan Z, Zucca F, Fariello R, Kordestani R, Zecca L . Identification and quantification of dolichol and dolichoic acid in neuromelanin from substantia nigra of the human brain. J Lipid Res. 2007; 48(7):1457-62. DOI: 10.1194/jlr.C700008-JLR200. View

13.

Ono K . The Oligomer Hypothesis in α-Synucleinopathy. Neurochem Res. 2017; 42(12):3362-3371. DOI: 10.1007/s11064-017-2382-x. View

14.

Ugalde C, Lawson V, Finkelstein D, Hill A . The role of lipids in α-synuclein misfolding and neurotoxicity. J Biol Chem. 2019; 294(23):9016-9028. PMC: 6556586. DOI: 10.1074/jbc.REV119.007500. View

15.

Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J . alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003; 302(5646):841. DOI: 10.1126/science.1090278. View

16.

Oliveira L, Falomir-Lockhart L, Botelho M, Lin K, Wales P, Koch J . Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells. Cell Death Dis. 2015; 6:e1994. PMC: 4670926. DOI: 10.1038/cddis.2015.318. View

17.

Sandal M, Valle F, Tessari I, Mammi S, Bergantino E, Musiani F . Conformational equilibria in monomeric alpha-synuclein at the single-molecule level. PLoS Biol. 2008; 6(1):e6. PMC: 2174973. DOI: 10.1371/journal.pbio.0060006. View

18.

Galvagnion C, Topgaard D, Makasewicz K, Buell A, Linse S, Sparr E . Lipid Dynamics and Phase Transition within α-Synuclein Amyloid Fibrils. J Phys Chem Lett. 2019; 10(24):7872-7877. PMC: 6937551. DOI: 10.1021/acs.jpclett.9b03005. View

19.

Lee H, Choi C, Lee S . Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem. 2001; 277(1):671-8. DOI: 10.1074/jbc.M107045200. View

20.

Wu G, Lu Z, Kulkarni N, Ledeen R . Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J Neurosci Res. 2012; 90(10):1997-2008. DOI: 10.1002/jnr.23090. View